Defining Criteria for Anti-Mannan Antibodies to Protect Against Candidiasis

Author(s): J. E. Cutler .

Journal Name: Current Molecular Medicine

Volume 5 , Issue 4 , 2005

Become EABM
Become Reviewer

Abstract:

Prevention of hematogenously disseminated candidiasis and mucocutaneous disease, including Candida vaginitis, through immunological approaches is appealing for the following reason. A long-acting and safe vaccine that protects against both serotypes of Candida albicans and other important species, such as C. tropicalis and C. glabrata, should significantly reduce the incidence of various forms of candidiasis by these etiologic agents. Through extensive experimentation on protective responses in experimental animals against Candida mannan components, others and we have evidence that antibodies specific for short-chain β-linked oligomannosides are protective against candidiasis. Although the mechanism of protection against vaginal infection requires further investigation, experimentally the ability of antibody to rapidly deposit high amounts of complement factor C3 onto the yeast cell wall is requisite for enhancing resistance against disseminated candidiasis.

Keywords: antibodies, host defense, candidiasis, candida albicans, protective antibodies, cell wall, surface mannans

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 4
Year: 2005
Page: [383 - 392]
Pages: 10
DOI: 10.2174/1566524054022576
Price: $58

Article Metrics

PDF: 2